Recent news on Pegvisomant

The Impact of Pegvisomant Treatment on Substrate Metabolism and ...  -  May 4, 2007
Journal of Clinical Endocrinology and Metabolism,Context: Pegvisomant is a specific GH receptor antagonist that is able to normalize serum IGF-I concentrations in most patients with acromegaly.

Endocrinology & Metabolism News, April 2007  -  Apr 4, 2007
Journal of Clinical Endocrinology and Metabolism,Pegvisomant caused artefactually low measured GH in most assay systems tested when pooled sera with known GH concentrations were spiked with the drug in

Treatment with Growth Hormone Receptor Antagonist in Acromegaly ...  -  Feb 6, 2007
Journal of Clinical Endocrinology and Metabolism,Aim: The aim of the current study was to evaluate the effect of short-term (6 months) and long-term (18 months) treatment with pegvisomant on cardiac

Gender, Body Weight, Disease Activity, and Previous Radiotherapy ...  -  Jan 5, 2007
Journal of Clinical Endocrinology and Metabolism,Context/Objective: To effectively normalize IGF-I in patients with acromegaly, various covariates may affect dosing and plasma concentrations of pegvisomant

Growth Hormone stimulates Osteoprotegerin Expression and secretion ...  -  Jan 3, 2007
Journal of EndocrinologySimilar results were obtained when the cells were exposed to a receptor antagonist of GH, pegvisomant at 50nM. GH exposure did not induce an increase in

McCune-Albright Syndrome and Acromegaly: Effects of ...  -  Dec 5, 2006
Journal of Clinical Endocrinology and Metabolism,...fractionated RT (45–55 Grays). Three patients (two with previous RT) were also prescribed pegvisomant. We analyzed the clinical ...

Baylor University, US, describe new medical findings  -  Nov 30, 2006
Therapeutics Daily (subscription) (press release),...developing directions of research. Study 1: Breast cancers with key phenotypes may respond to pegvisomant. "Mammary gland development ...

Reductions of Circulating Matrix Metalloproteinase 2 and Vascular ...  Nov 6, 2006
Aim: This study assessed plasma MMPs and VEGF levels in patients with active acromegaly (IGF-I > 130% upper limit of normal), and on treatment with pegvisomant ... -Journal of Clinical Endocrinology and Metabolism, McCune-Albright Syndrome and Acromegaly: Effects of ...  -  Dec 5, 2006
Journal of Clinical Endocrinology and Metabolism,Three patients (two with previous RT) were also prescribed pegvisomant. We analyzed the clinical features of acromegaly, GH, and IGF-I concentrations and

Baylor University, US, describe new medical findings  -  Nov 30, 2006
Therapeutics Daily (subscription) (press release),In this study we investigated the effect of a GH antagonist, pegvisomant (Somavert, Pfizer), on normal mammary gland development and breast cancer xenograft

Pegvisomant for the Treatment of gsp-Mediated Growth Hormone ...  Aug 7, 2006
Objective: We examined efficacy of the GH receptor antagonist, pegvisomant, in controlling gsp oncogene-mediated GH excess and skeletal disease (fibrous ... -Journal of Clinical Endocrinology and Metabolism

Ipsen and Tercica to Enter into Worldwide Strategic Collaboration ...  Jul 18, 2006
MIDAS/Ex-manufactures as a percentage of sales of sustained release formulations of the specific molecules lanreotides, octreotide and pegvisomant -- in class ... -Canada NewsWire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional